Intravasation, the active entry of primary tumor cells into the vasculature, remains the least studied step in the metastatic cascade. Protease-mediated escape and stromal invasion of tumor cells represent widely-accepted processes leading up to the intravasation step.
Introduction
Deaths from cancer occur mainly because tumor cells metastasize from the primary tumor site to secondary vital tissues and organs likely by using the new angiogenic vasculature of the tumor as conduits. Metastasis, which is a complex multistep process, is still one of the major unsolved problems in cancer biology. Intravasation, the step in metastasis whereby escaping primary tumor cells enter the vasculature, is the least studied process in the entire metastatic cascade. Intravasation is experimentally understudied because there are very few if any in vivo models that accurately recapitulate the entry of tumor cells into the vasculature and also allow for quantification of the intravasation events. Furthermore, real-time imaging of escaping primary tumor cells and in vivo microscopic analysis of the structure and functionality of tumor-associated vasculature remain problematic for most laboratories.
Because of these modeling and methodological issues, no clear signature molecules which directly contribute to the intravasation event have been identified. However, several mechanisms have been linked to the processes and events leading up to the intravasation step, such as primary tumor cell escape and migration and protease-mediated tumor cell invasion. In regard to the latter, proteolytic degradation of the basement membrane and stromal matrix by specific members of the matrix metalloproteinase (MMP) family of enzymes could provide functional molecular links to tumor cell escape, transendothelial migration and possibly to tumor cell-mediated active entry into the vasculature. The MMPs comprise a family of zinc-dependent endopeptidases that proteolytically modify the extracellular matrix in the primary tumors and metastatic sites as well as cleave distinct molecules on the surface of tumor and stromal cells (1-3).
A number of MMP genes have been linked to development and progression of squamous cell carcinomas (SCCs), which constitute 90% of head and neck cancers, the fifth leading cause of cancer-related deaths (4) . The MMP genes that have been linked to SCC progression, include Mmp1, 2, 3, 7, 9, 10, 11, 12 , and 13, most of which are overexpressed in the SCC tissue compared to normal mucosa (4, 5) . However, a remarkable, more than 70-fold differential between normal oral mucosa and oral SCCs was demonstrated for the Mmp1 gene, which was found to be third best predictor among 25 signature genes (5) , suggesting a critical role of MMP-1 protein in SCC progression Furthermore, while the expression of many MMPs in primary SCCs is associated with stromal or inflammatory cells rather than carcinoma cells, MMP-1 protein expression has been attributed to cancer cells at least in oral SCCs (5) . In addition, MMP-1 has shown up as one of the signature genes for the metastatic phenotype for human breast cancers (6) (7) (8) and has also been validated as part of a set of 63 genes associated with the progression and metastasis of advanced cervical carcinomas (9) .
All these considerations clearly warrant mechanistic study of the functional contribution of tumor-produced MMP-1 to metastasis of SCCs.
To functionally analyze the role of MMP-1 in overall metastatic dissemination and specifically the intravasation step of SCCs, we employed the human epidermoid carcinoma cell line, HEp3, which is highly metastatic in both mice and chick embryos (10, 11) 
Material and Methods

Cell lines and Maintenance
Human endothelial EA.hy926 cells (CRL-2922) were obtained from the American Type Culture Collection (ATCC, Manassas, MA). Prior to this study, the cells were verified for expression of human CD44, CD31, CD105 and Factor VIII-related antigen by immunocytochemistry. The cells were also tested and proved negative for mycoplasma contamination. Human head and neck carcinoma cell line Detroit 562 was obtained from ATCC and used within 6 month after purchasing. Unless specified, the cells were maintained as monolayer cultures in a humidified incubator at 5% CO 2 and 37ºC. Cell passaging was performed by brief exposure of cell monolayer to minimal volume of trypsin-EDTA solution followed by plating of detached cells in fresh DMEM-10% FCS.
Generation of HEp3 dissemination variants
Human epidermoid carcinoma HEp3-hi/diss cells were originally isolated from a neck lymph node metastasis of a patient diagnosed with head and neck carcinoma (12) . The HEp3 cells were not deposited to any tissue or cell bank. The original HEp3 cell line was thoroughly characterized in animal models by Dr. L. Ossowski (13, 14) and became widely used in cancer research. In our laboratory, the parental HEp3 cells are maintained since 1986 (15) and have been repeatedly used in various cancer research studies (11, (16) (17) (18) (19) . The ability of HEp3 cells to form metastatic tumors after orthotopic implantations into the tongue and buccal mucosa of nude mice was verified in our laboratory in 2012.
The Hep3-hi/diss cells were generated from primary tumors developing from parental HEp3 cells grafted on the CAM of chick embryos as described (20) . Briefly, CAM tumors were dissected from the CAM, minced and incubated with dispase (1.25 unit/mL) to generate single cell suspension. After washing, the cells were placed into Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS (HyClone, Logan, UT), sodium pyruvate (Invitrogen) and 10 μg/ml gentamicin (Gibco) (D-10) . Aliquots of primary cells were frozen at day 5 to provide a supply of HEp3 cells at low passage numbers. The cells, which were maintained in culture for 25 days or less, exhibited high levels of spontaneous dissemination and were designated as HEp3-hi/diss. The cells, which were cultured for more than 75 days, lost dissemination capacity and were designated as HEp3-lo/diss. The parental HEp3, HEp3-hi/diss and HEp3-lo/diss cells were tested for mycoplasma contamination and confirmed to be negative.
Intravasation and spontaneous metastasis model
Chick embryo spontaneous metastasis assays were performed as described (21). 
Experimental metastasis model
Embryos were inoculated with 5×10 4 tumor cells. At 2 hr (cell arrest) or 5 days (tissue colonization), the portions of the CAM and liver were analyzed by Alu-qPCR to determine numbers of human cells. CAM colonization was also examined by fluorescence microscopy as described (22) . For this analysis, the cells were pre-labeled with 5 µM CellTracker Green, while the CAM vasculature was highlighted with Rhodamine-conjugated Lens culinaris agglutinin (LCA; Vector Labs, Burlingame, CA).
Intramesodermal microtumor model for tumor cell escape and stromal invasion
HEp3-hi/diss cells treated with control and MMP-1 siRNA constructs were labeled with 5 µM CellTracker Green and resuspended at 2x10 6 /ml. Five to seven small boluses of tumor cells (3-5 µl) were injected directly into the CAM mesoderm of day 10 chick embryos incubated ex ovo as described (23). Five days after cell injections, embryos were inoculated with rhodamin-conjugated LCA to highlight the vasculature. Portions of the CAM with microtumors were imaged using a Carl Zeiss AxioImager microscope. Quantification of tumor cell escape and invasion was performed using ImageJ software (NIH, Bethesda, MD).
The mean of invasion distances from the microtumor-CAM border was determined for individual microtumors. A total of 11 to 13 individual microtumors from 6 to 8 embryos were analyzed for each variable in 2-3 independent experiments.
Microtumor model and measurement of intratumoral vascular permeability
HEp3-hi/diss cells were treated with control or MMP-1 siRNA constructs, pre-labeled with CellTracker Green and mixed with neutralized type I collagen (Becton Dickinson, Bedford, MA) at 1x10 7 cells per ml and six 10-µl aliquots were placed separately on the top of the intact CAM of embryos developing for 9 or 10 days ex ovo to generate microtumors After 6-day incubation, Rhodamine-conjugated LCA was inoculated i.v. to highlight the CAM vasculature. The portions of the CAM containing microtumors were visualized in a fluorescent Olympus microscope. The images were analyzed for the overall structure of intratumoral vessels and their diameter.
To measure intratumoral vasculature permeability, CAM microtumors were generated from unlabeled HEp3-hi/diss cells. The developing microtumors were treated topically with 20 µL of vehicle (1%DMSO in PBS) or solutions of PAR1 antagonists, SCH79797 or RWJ56110 (Tocris Bioscience, UK) applied at 5 µM to 50 µM concentrations. The treatments were performed on days 1, 3 and 5 or days 2 and 4. On day 6, embryos were inoculated first with the permeable, TRITC-conjugated dextran with mol. wt. of 155 kDa.
Non-permeable FITC-conjugated dextran with mol. wt. of 2,000 kDa was inoculated 45-60 min later, displacing the 155-kDa dextran from the vasculature. Images of microtumors and intratumoral vasculature were acquired in red and green fluorescence channels at the fixed exposure time, and individual microtumors were excised and lysed in 0.3 ml modified RIPA buffer. Levels of red fluorescence, reflecting amounts of tissue-retained low mol. wt. TRITCconjugated dextran, were measured in lysates of individual tumors at 576 nm (excitation at 557 nm). Levels of green fluorescence, reflecting the volume of perfusable vasculature was measured at 516 nm (excitation at 492 nm).
Statistical analysis
Data processing and statistical analyses were performed using GraphPad Prism Software (GraphPad Software Inc., San Diego, CA). For the chick embryo assays, percent changes were calculated from the pooled differences determined as the ratios of numerical values for individual embryos over a mean of the control in the corresponding experiment. 
Results
Metastatic potential of HEp3 carcinoma variants correlates with MMP-1 expression
Comparative analysis of high and low disseminating HEp3 variants was performed in spontaneous versus experimental metastasis models to identify those temporal steps of the dissemination cascade where non-metastatic and metastatic carcinoma cells manifest most of their functional differential. In a spontaneous metastasis model, HEp3-hi/diss and HEp3-lo/diss cells gave rise to primary tumors with almost equal weight (approximately 166±6 mg), indicating similar tumorigenic potentials of HEp3 variants. However, only HEp3-hi/diss cells exhibited high levels of dissemination compared to their late-passage counterparts, reflected in a 25-fold differential in CAM intravasation and 10-fold differential in liver metastasis (P<0.0001) (Fig. 1A) .
Whether overall metastatic potential of HEp3 variants depended on their ability to complete the late steps of cell dissemination was tested in an experimental metastasis model involving tumor cell inoculations directly into the blood circulation and thus bypassing the early events of metastasis, including primary tumor formation and tumor cell intravasation.
The HEp3-lo/diss and HEp3-hi/diss cells did not differ in their 2-hr arrest in the CAM vasculature, indicating their similar ability to interact with the luminal surface of vascular endothelium. Furthermore, HEp3 variants differed only by 3 to 4 fold in their ability to colonize the CAM and liver tissue as measured at day 5 after cell inoculations (Fig. 1B) .
When compared with the 10-25 fold differentials in spontaneous metastasis, it appears that the dissemination disparity between the HEp3 variants lies primarily in their ability to complete early steps of the metastatic cascade, preceding and including the process of intravasation into the vasculature.
Since MMPs have been strongly implicated in progression of different cancer types, we thought to identify those distinct MMP(s), the expression of which would correlate with the dissemination potential of the HEp3 carcinoma variants. We first evaluated HEp3-hi/diss cells for overall expression of several candidate MMP genes, including Mmp1, 2, 3, 7, 8, 9, 10, 13 Mmp8 expression was higher in HEp3-lo/diss cells (Fig. 1C) , the latter consistent with reports documenting reciprocal correlation between MMP-8 levels and tumor aggressiveness (24-26). In contrast, the levels of Mmp1 expression were consistently and significantly higher in HEp3-hi/diss cells (P<0.01), exceeding by 3-fold the levels observed in the HEp3-lo/diss variant ( Fig. 1C) and suggesting that this collagenase may contribute to metastatic spread of aggressive HEp3 cells.
The relative MMP-1 production by HEp3-hi/diss and HEp3-lo/diss cells was analyzed by western blotting of conditioned medium (Fig. 1D) . Comparison with the position of the residual zymogen and activated forms of recombinant proMMP-1 allows for a conclusion that MMP-1 is secreted by HEp3 cells mainly as a ~52-kDa proenzyme. Characteristically, the production of proMMP-1 gradually decreased with the time HEp3-hi/diss cells spent in culture, concomitantly with the loss of intravasation and metastatic capacity manifested in the resulting HEp3-lo/diss cells (>75 days in culture). Thus, the overexpressed MMP-1 gene and its protein product may determine in part the dissemination phenotype and metastatic fate of epidermoid carcinoma cells.
Functional significance of MMP-1 in HEp3-hi/diss intravasation and metastasis
To examine the specific contribution of MMP-1 to intravasation of carcinomas, HEp3-hi/diss cells were transfected with MMP-1 shRNA construct, generating a cell line that stably expressed 90% less MMP-1 protein as compared with control shRNA-treated cells ( Fig. 2A,   left) . In addition, MMP-1 silencing was achieved by transient transfection of HEp3-hi/diss cells with siRNA constructs, resulting in a profound (95-99%) and relatively long-lasting downregulation of MMP-1 protein production ( Fig. 2A, right) . The lack of major off-target effects of MMP-1 silencing on other MMPs is indicated by similar levels of secreted MMP-2 in HEp3-hi/diss cells treated either with control or MMP-1 shRNA ( Fig. 2A, zymograms) .
Furthermore, the unchanged levels of MMP-2 forms (namely, 68-kDa proenzyme, 64-kDa activation intermediate and 62-kDa fully activated enzyme) ( Fig. 2A) , are a valid indicator that the activity levels of MMP-14 also have not been affected by down-regulation of MMP-1 since MMP-14 is the only naturally expressed MMP responsible for MMP-2 processing and activation (27, 28). siRNA constructs did not affect the tumorigenic capacity of HEp3-hi/diss cells (Fig. 2B, top) .
In agreement, control and MMP-1-silenced HEp3-hi/diss transfectants showed no significant difference in proliferation rates in 2D cultures and, more importantly, in 3D collagen gels (Suppl . Fig. S1 ). However, the deficiency in MMP-1 protein in HEp3-hi/diss cells caused either by shRNA or siRNA treatments was associated with a substantial, from 80% to 97% decrease in both CAM intravasation and liver metastasis (Fig. 2B, middle and bottom) .
Immunohistological analysis demonstrated the HEp3-hi/diss tumors originating from control and MMP-1-silenced cells exhibited overall similar morphology. Although MMP-1-deficient tumors manifested a more intense staining for tumor cells at the tumor-stroma border, no significant differences were observed between invasive fronts of control and MMP-1 siRNA tumors ( Fig. 2C and 2D) . was confirmed by western blot analysis (Fig. 3A) , but while it did not affect significantly their ability to form primary tumors, it caused a considerable, from 60% to 70% decrease in the levels of CAM intravasation and liver metastasis as compared to the cells transfected with control siRNA (P<0.0001) ( (Fig. 3B) . Moreover, supplementation of MMP-1 protein to primary tumors also significantly increased intravasation levels of tumor cells escaping from HEp3-lo/diss primary tumors ( Fig. 3C) , supporting that MMP-1 deficiency was one of the contributing factors in low dissemination capacity of HEp3-lo/diss cells.
Functional contribution of MMP-1 to HEp3-hi/diss stromal invasion
We next analyzed whether MMP-1 produced by HEp3-hi/diss cells functionally contributes to the escape from primary tumors and stromal invasion since these processes are likely prerequisites of tumor cell intravasation. Putative involvement of MMP-1 in stromal invasion was examined in an in vivo stromal invasion model, in which human tumor cells are injected directly into the mesoderm of chick embryos developing ex ovo and allowed to form intramesodermal microtumors (22). Cell escape from these microtumors and invasion of the escaped cells within mesodermal stroma is then visualized by epifluorescence microscopy. In this assay, HEp3-hi/diss cells treated with MMP-1 siRNA constructs showed a diminished escape from microtumors and also demonstrated approximately 45% decrease in the migration distance compared to siRNA control (P<0.0001) (Fig. 4A) . The most plausible mechanism for the observed effects would involve diminished collagen degradation mediated by MMP-1, a potent collagenase, which could modify the collagen-rich stroma of the CAM.
However, this conclusion is not supported by a complete lack of any inhibitory effects of MMP-1 silencing on the overall adhesive, migratory and invasive capacities of HEp3-hi/diss cells tested in vitro (Suppl. 
HEp3-derived MMP-1 regulates the microarchitecture of intratumoral blood vessels
To investigate whether the effects of MMP-1 on tumor cell invasion and intravasation in vivo may be indirect and independent from the putative collagenolytic activity of MMP-1 on matrix degradation, we examined the involvement of MMP-1 in the induction of tumor angiogenesis, an MMP-dependent process that ultimately provides aggressive cancer cells with conduits for vascular spreading. To address this possibility, we evaluated the extent of angiogenic network development within intramesodermal microtumors originating from HEp3-hi/diss cells treated with either control or MMP-1 siRNA constructs. Both tumor types exhibited comparable numbers of CAM blood vessels coalescing towards the border of intramesodermal microtumors (Fig. 4B) . However, intratumoral angiogenic vessels networks appear distinctly different between control and MMP-1-silenced microtumors. Thus, more than 70% of control microtumors contained well-developed, perfusable intratumoral angiogenic blood vessels. In contrast, almost 90% of MMP-1-deficient HEp3-hi/diss microtumors failed to develop robust intratumoral angiogenic networks and therefore these intramesodermal microtumors presented with rather thin, poorly perfused blood capillaries ( Fig. 4C and 4D) . Thus, the average diameter of five most prominent intratumoral blood vessels was 25 µm within individual control microtumors, but reached only 12 µm in microtumors developing from MMP-1-silenced cells (Fig. 4E) . More detailed distribution analysis indicated that almost 60% of blood vessels in control HEp3-hi/diss microtumors were of ≥20 µm in diameter, whereas an 80% majority of vessels in MMP-1-deficient microtumors had a lumen diameter less than 15 µm and only 7% of blood vessels were ≥20 µm in diameter (Fig. 4F) . Together these findings suggested that under in vivo conditions, the MMP-1 produced by aggressive HEp3 cells is involved in the regulation of intratumoral angiogenesis and the overall structure of the tumor neovasculature.
MMP-1 regulates development of intratumoral angiogenic blood vessels that sustain
HEp3-hi/diss cell intravasation
The above notion was further investigated in a modification of the spontaneous metastasis assay, which involves the establishment of topical CAM microtumors in ex ovoincubated embryos by grafting 5-6 collagen droplets each containing 1x10 5 cells (Fig. 5A ). (Fig. 5B) . Notably, this inhibition of tumor dissemination occurred in the absence of significant cell invasion into the surrounding stroma (Fig. 5C) , further suggesting the involvement of mechanisms other than MMP-1-mediated collagen-remodeling. To probe for this notion, we analyzed possible correlations between the levels of MMP-1-mediated tumor cell dissemination and the structure of intratumoral vessels visualized by epifluorescence microscopy of topical CAM tumors. Both control and MMP-1-silenced microtumors triggered robust vascular responses, attracting large and medium size CAM blood vessels, which under low magnification appear to converge onto topically developing microtumors (Fig. 5C) . However, quantitative analysis of images acquired at higher magnification indicated that almost 90% of control microtumors had well-developed intratumoral angiogenic networks as opposed to less than 40% of siMMP-1 microtumors. Western blot analysis of CAM microtumors excised from individual embryos confirmed that MMP-1 siRNA silencing in HEp3-hi/diss cells was still sustained in microtumor tissue at the end of the 6 day-long experiment ( Fig. 5D) . This differential in MMP-1 expression closely correlated with the pattern and extent of intratumoral vasculature development manifested in a higher density of well-defined, lumen-containing angiogenic vessels within control microtumors (Fig. 5E, top panels) . In contrast, MMP-1-deficient microtumors exhibited a substantially reduced density of lumen-containing vessels, most of which appeared poorly perfused and less interconnected (Fig. 5E, bottom panels) . Furthermore, the angiogenic vessels within the two types of microtumors differed significantly in their mean lumen diameter (12.1±0.9 µm in control tumors versus 6.9±0.3 µm in MMP-1-deficient tumors; P<0.001) (Fig. 5F, bars on the left) . In addition, diameter distribution analysis indicated that approximately 30% of blood vessels in control HEp3-hi/diss microtumors contained lumens with diameter of more than 15 µm, whereas microtumors developing from siMMP-1-treated cells were almost completely deprived of this size of blood vessels (28.3±4.2% versus 0.8±0.8%, P<0.0001) (Fig. 5F , bars on the right). Importantly, this significant differential in the size and overall quality of the intratumoral angiogenesis is highly comparable with the intravasation and metastasis differentials displayed by the two cell types as measured in the same model system (Fig. 5B) . intratumoral angiogenic vasculature capable of sustaining tumor cell intravasation, whereas MMP1 silencing appears to severely compromise vascular microarchitecture by narrowing vessel diameters, which in turn, would prevent tumor cell intravasation.
MMP-1 regulates endothelial permeability and HEp3-hi/diss transendothelial migration
Tumor cell penetration into vessels via an MMP-1-mediated disruption of the endothelial barrier can constitute an additional mechanism whereby carcinoma cell-produced MMP-1 would facilitate intravasation independent of the collagenolytic activity of MMP-1 and its putative effects on stromal invasion. Since MMP-1-silencing did not affect the overall adhesive, migratory and invasive capacities of HEp3-hi/diss cells (Suppl. Fig. S3 ), we further explored the possibility that the ability of tumor cells to cross over an endothelial barrier may not depend on collagenolytic activity of MMP-1. This was investigated in a Transwell assay, which combines measurement of endothelium permeability by Evans blue exudation with coordinated quantification of tumor cell transendothelial migration in an environment free of interstitial collagen (Fig. 6) . Control, MMP-1 competent HEp3-hi/diss cells, but not the MMP-1-silenced cells (Fig. 6A) , were able to induce substantial Evans blue diffusion (Fig. 6D) , strongly implicating carcinoma cell-produced MMP-1 in the disruption of endothelium integrity. This notion was further affirmed when plasmin-activated recombinant MMP-1 ( Fig.   6B ) was able to rescue dampened levels of endothelial permeability induced in the presence of MMP-1-silenced HEp3-hi/diss cells (Fig. 6D, left) . Furthermore, control HEp3-hi/diss cells exhibited approximately 3-4-fold higher rates of transendothelial migration as compared with their MMP-1-silenced counterparts, thereby establishing a strong positive link between MMP-1 production by carcinoma cells and their ability to cross endothelial barriers. This link is further re-enforced by more than 2-fold increase of transendothelial migration of MMP-1-silenced cells by addition of activated exogenous MMP-1 (Fig. 6D, right) .
To verify whether carcinoma-produced MMP-1 disrupted endothelium integrity through processes involving PAR1 activation (29), we used a specific PAR1 antagonist, SCH79797, which was added at 5 µM into Transwells. The PAR1 antagonist significantly and concomitantly diminished the ability of MMP-1-competent HEp3-hi/diss cells to induce endothelial permeability and cross over the transendothelial barrier (Fig. 6D, black bars) .
Correspondingly, these two diminished capacities of the MMP-1-deficient cells were rescued by the addition of exogenous active MMP-1 (Fig. 6D, horizontally-striped bars) . Since gene expression of PAR1 in the targeted endothelial cells is 10-fold higher than in HEp3-hi/diss cells and has not been affected by siRNA downregulation of MMP-1 (Fig. 6C) No exudation of low mol. wt. dextran was observed in the CAM tissue distal to the tumors (Fig. 7A, left) . However, the permeable dextran was detected at significant levels within control MMP-1-competent microtumors as evidenced by diffuse red fluorescence (Fig. 7A, middle) . In contrast, the intensity of red fluorescence was significantly reduced by MMP-1 silencing, (Fig. 7A, right) , which could be appreciated more readily in a monochromatic tone (Fig. 7A, lower panels) . Permeable dextran exudation was quantified in the lysates of individual microtumors either relative to the volume of perfusable intratumoral vasculature or as an independent parameter. This analyses confirmed that specific vascular permeability in MMP-1-deficient tumors was diminished 2.3-fold (P<0.05) compared to control microtumors (Fig. 7B, top) . Furthermore, the comparison of absolute levels of dextran exudation independent of the volume of perfusable vasculature in the individual tumors indicated approximately a 10-fold differential in the overall vascular permeability between control and MMP-1-silenced microtumors (Fig. 7B, bottom) . 
Similar to MMP-1 silencing, SC79797 caused a significant reduction in the levels of permeable dextran exudation compared to the vehicle-control tumors as depicted visually or quantified fluorometrically (Fig. 7C and 7D) . When related to perfusable vascular volume, specific vascular permeability in SC79797 -treated tumors was diminished 2.4-fold (P<0.05), whereas the overall levels of dextran exudation indicated a more that 5-fold decrease caused by this specific inhibitor of PAR1 signaling (P<0.005). Comparable results were obtained for the PAR1 antagonist RWJ56110 (Suppl. Fig. S4) , further strengthening the observed inhibitory effects of SCH79797. In addition to significant diminishment of vascular permeability, the treatment with SCH79797 also reduced the levels of HEp3-hi/diss CAM intravasation (Suppl. 
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